Prevalence of Pathogenic Germline Variants in Patients With Gastric Cancer Ascertained Through Multigene Panel Testing
JCO Precision Oncology · 2025-06 · (9)
DOI: 10.1200/po-24-00620 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Precision Oncology, 2025-06. Verfasst von Ophir Gilad und 9 weiteren Autor:innen. Beteiligte Einrichtung: Section of Gastroenterology, Hepatology and Nutrition, University of Chicago, Chicago, IL. Hauptthemen laut MEDLINE: Stomach Neoplasms, Germ-Line Mutation, Genetic Testing. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 39 Literaturangaben.
Abstract (Originalsprache)
PURPOSE The prevalence of pathogenic/likely pathogenic germline variants (PGVs) in gastric cancer (GC) predisposition genes is not well understood. We aimed to determine this in patients with GC undergoing germline genetic testing at a large commercial laboratory. METHODS This was a cross-sectional study. Retrospective review of genetic testing in patients with GC at a commercial laboratory (Invitae Corp) from March 2015 to July 2023 was performed. Prevalence of PGVs was determined and compared with a control cohort of 20,139 individuals unaffected by cancer. Data were abstracted from test requisition forms. RESULTS In total, 3,706 patients with GC underwent genetic testing, of which 494 (13.3%) patients carried PGVs, 1,200 (32.4%) had variants of uncertain significance, and 1,890 (51%) had negative testing. PGVs were identified in 38 genes, of which 385 of 494 (77.9%) were in a gene previously associated with GC, including 35% in homologous recombination repair genes ( BRCA1 , BRCA2 , PALB2 , and ATM ), 19.5% in Hereditary Diffuse GC genes ( CDH1 and CTNNA1 ), and 17.4% in Lynch syndrome genes ( MLH1 , MSH2 , MSH6 , PMS2 , and EPCAM ). Comparing the GC cohort with the unaffected cohort, it was found that there was significant enrichment of PGVs in most GC-associated genes, except for APC , EPCAM , MUTYH , and PMS2 . Odds of carrying a PGV was increased significantly in males and patients with a personal history of another cancer with odds ratio (OR) of 1.3 (95% CI, 1.1 to 1.6) and OR, 1.4 (95% CI, 1.1 to 1.7), respectively. CONCLUSION In this large study of genetic testing in patients with GC, more than one in eight patients referred for germline testing was found to harbor a PGV in a cancer predisposition gene, which is higher than previous estimates. Most PGVs were identified in genes previously associated with GC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Section of Gastroenterology, Hepatology and Nutrition, University of Chicago, Chicago, IL.
- Invitae Corporation, San Francisco, CA.
- Division of Human Genetics, Department of Internal Medicine, The Ohio State University, Columbus, OH.
- Department of Gastroenterology, Hepatology and Nutrition, Cleveland Clinic, Cleveland, OH.
ORCID-Profile: Ophir Gilad, Emma Keel, Emily M Russell, Sarah M Nielsen, Brandie Heald, Edward D Esplin, Maegan E Roberts
Zitieren
APA
Gilad, O., Keel, E., Russell, E. M., Nielsen, S. M., Heald, B., Esplin, E. D., Korn, W. M., Roberts, M. E., Burke, C. A., & Kupfer, S. S. (2025). Prevalence of Pathogenic Germline Variants in Patients With Gastric Cancer Ascertained Through Multigene Panel Testing. JCO Precision Oncology. https://doi.org/10.1200/po-24-00620
Vancouver
Gilad O, Keel E, Russell EM, Nielsen SM, Heald B, Esplin ED, et al. Prevalence of Pathogenic Germline Variants in Patients With Gastric Cancer Ascertained Through Multigene Panel Testing. JCO Precision Oncology. 2025. doi:10.1200/po-24-00620
BibTeX
@article{Gilad2025,
author = {Gilad, Ophir and Keel, Emma and Russell, Emily M and Nielsen, Sarah M and Heald, Brandie and Esplin, Edward D and Korn, W Michael and Roberts, Maegan E and Burke, Carol A and Kupfer, Sonia S},
title = {Prevalence of Pathogenic Germline Variants in Patients With Gastric Cancer Ascertained Through Multigene Panel Testing},
journal = {JCO Precision Oncology},
year = {2025},
number = {9},
doi = {10.1200/po-24-00620}
}
EUVIMED